TII
13.5.2024 15:37:31 CEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today launched a second iteration of its renowned large language model (LLM) – Falcon 2. Within this series, it has unveiled two groundbreaking versions: Falcon 2 11B, a more efficient and accessible LLM trained on 5.5 trillion tokens with 11 billion parameters, and Falcon 2 11B VLM, distinguished by its vision-to-language model (VLM) capabilities, which enable seamless conversion of visual inputs into textual outputs. While both models are multilingual, notably, Falcon 2 11B VLM stands out as TII's first multimodal model – and the only one currently in the top tier market that has this image-to-text conversion capability, marking a significant advancement in AI innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513516248/en/
Falcon Image Caption Generator (Photo: AETOSWire)
Tested against several prominent AI models in its class among pre-trained models, Falcon 2 11B surpasses the performance of Meta’s newly launched Llama 3 with 8 billion parameters (8B), and performs on par with Google’s Gemma 7B at first place (Falcon 2 11B: 64.28 vs Gemma 7B: 64.29), as independently verified by Hugging Face, a US-based platform hosting an objective evaluation tool and global leaderboard for open LLMs. More importantly, Falcon 2 11B and 11B VLM are both open-source, empowering developers worldwide with unrestricted access. In the near future, there are plans to broaden the Falcon 2 next-generation models, introducing a range of sizes. These models will be further enhanced with advanced machine learning capabilities like 'Mixture of Experts' (MoE), aimed at pushing their performance to even more sophisticated levels.
All of TII’s AI models released to date have consistently ranked in the top tier globally, as the most powerful open-source LLMs. The new scaled-down and versatile Falcon 2 11B models are set to give TII greater market adoption in the ever-evolving world of generative AI.
Falcon 2 11B models, equipped with multilingual capabilities, seamlessly tackle tasks in English, French, Spanish, German, Portuguese, and various other languages, enriching their versatility and magnifying their effectiveness across diverse scenarios. Falcon 2 11B VLM, a vision-to-language model, has the capability to identify and interpret images and visuals from the environment, providing a wide range of applications across industries such as healthcare, finance, e-commerce, education, and legal sectors. These applications range from document management, digital archiving, and context indexing to supporting individuals with visual impairments. Furthermore, these models can run efficiently on just one graphics processing unit (GPU), making them highly scalable, and easy to deploy and integrate into lighter infrastructures like laptops and other devices.
H.E. Faisal Al Bannai, Secretary General of ATRC and Strategic Research and Advanced Technology Affairs Advisor to the UAE President, said: "With the release of Falcon 2 11B, we've introduced the first model in the Falcon 2 series. While Falcon 2 11B has demonstrated outstanding performance, we reaffirm our commitment to the open-source movement with it, and to the Falcon Foundation. With other multimodal models soon coming to the market in various sizes, our aim is to ensure that developers and entities that value their privacy have access to one of the best AI models to enable their AI journey."
Speaking on the model, Dr. Hakim Hacid, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: “AI is continually evolving, and developers are recognizing the myriad benefits of smaller, more efficient models. In addition to reducing computing power requirements and meeting sustainability criteria, these models offer enhanced flexibility, seamlessly integrating into edge AI infrastructure, the next emerging megatrend. Furthermore, the vision-to-language capabilities of Falcon 2 open new horizons for accessibility in AI, empowering users with transformative image to text interactions.”
The versatility of Falcon 2 11B has also led TII to consider working on more exciting GenAI innovations. Among these will be the adoption of a new type of machine learning capability known as the aforementioned ‘Mixture of Experts’. This method involves amalgamating smaller networks with distinct specializations, ensuring that the most knowledgeable domains collaborate to deliver highly sophisticated and customized responses – almost like having a team of smart helpers who each know something different and work together to predict or make decisions when needed. This approach not only improves accuracy, but it also accelerates decision-making, paving the way for more intelligent and efficient AI systems.
Falcon 2 11B is licenced under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513516248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
